Segment Reporting - Schedule of Segment Profit or Loss, Including Significant Segment Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenues [Abstract]
Total revenues	$ 6,235	$ 2,826
Research and development expenses
Total DNTH103 program-related expenses	54,395	18,024
Total research and development expenses	83,105	32,841
General and administrative expenses
Total general and administrative expenses	24,994	18,159
Other income, net	16,895	4,619
Net Income (Loss)	(84,969)	(43,555)
License [Member]
Revenues [Abstract]
Total revenues	326	0
Clinical operation activities [Member]
Research and development expenses
Total DNTH103 program-related expenses	25,764	4,931
CMC activities [Member]
Research and development expenses
Total DNTH103 program-related expenses	19,494	5,969
Preclinical study costs [Member]
Research and development expenses
Total DNTH103 program-related expenses	8,537	7,024
Personnel and Related Costs [Member]
Research and development expenses
Total research and development expenses	16,638	9,515
General and administrative expenses
Total general and administrative expenses	8,249	9,600
Share Based Compensation [Member]
Research and development expenses
Total research and development expenses	5,576	897
General and administrative expenses
Total general and administrative expenses	7,318	2,003
Discovery Expenses [Member]
Research and development expenses
Total research and development expenses	2,117	1,426
Other costs [Member]
Research and development expenses
Total DNTH103 program-related expenses	4,379	2,979
Total research and development expenses	600	100
General and administrative expenses
Total general and administrative expenses	9,427	6,556
Related Party [Member] | License [Member]
Revenues [Abstract]
Total revenues	$ 5,909	$ 2,826